Scientists from the Lebanese American University investigated the role of acetyl-CoA synthetase short chain family member 2 (ACSS2) in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Researchers from Universidad del País Vasco and affiliated organizations presented data from a study that aimed to investigate the role of macrophage receptor with collagenous structure (MARCO) in intrahepatic cholangiocarcinoma.
Medigene AG and Epimab Biotherapeutics Inc. have entered a strategic codevelopment agreement to research and develop off-the-shelf T-cell receptor (TCR)-guided T-cell engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors.
Researchers from Medizinische Hochschule Hannover and affiliated organizations reported data from studies aimed to identify non-coding microRNAs (miRNAs) with therapeutic potential against liver fibrosis in hepatocellular carcinoma (HCC). Functional screening of patient-derived primary human hepatic myofibroblasts, followed by in vivo validation in mouse models of fibrosis, were performed in search of antifibrotic miRNAs.
Derm-Biome Pharmaceuticals Inc. has reported findings from a study of its topical drug DB-007-5 in a well-established preclinical model of human atopic dermatitis.
Avian influenza viruses, particularly the H5 and H7 subtypes, can cause widespread outbreaks in birds and pose a significant zoonotic risk due to their potential to mutate and develop the ability for human-to-human transmission. Researchers from the University of Muenster described the preclinical efficacy of zapnometinib, a selective MEK1/2 inhibitor, against H5N1 clade 2.3.4.4b.
Mutations in the TP53 gene occur in approximately half of human cancer types, with the TP53 Y220C mutation found in 1% of all solid tumors. Researchers from PMV Pharmaceuticals Inc. and collaborators described the effect of rezatapopt (PC-14586), a first-in-class selective p53 reactivator designed to reinstate p53 Y220C mutant function.
Shanghai Pharmaceuticals Holding Co. Ltd. has disclosed aza-ergoline derivatives acting as dopamine D2 receptor and/or D3 receptor agonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), depression, erectile dysfunction, substance abuse and dependence, restless legs syndrome, schizophrenia, Parkinson’s and Alzheimer’s disease, among others.
Enanta Pharmaceuticals Inc. has developed mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis, pulmonary arterial hypertension, irritable bowel syndrome, inflammatory, dermatological and respiratory disorders, among others.
Terremoto Biosciences Inc. has synthesized new 3H-imidazo[4,5-b]pyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKB-α) inhibitors reported to be useful for the treatment of cancer.
RSS
